Close Menu

J&J

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.

The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.

Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.

Using J&J's CellSearch platform, researchers have demonstrated the expression of PD-L1 on CTCs, a finding they believe they are the first to show.

Three new assays were presented in posters at April's Clinical Virology Symposium.

Gathering the Data

IBM and its partners look to combine health information to develop a health platform for the Watson supercomputer.

NEW YORK (GenomeWeb News) – Janssen Biotech and Johnson & Johnson Innovation today announced a research alliance with the Icahn School of Medicine at Mount Sinai to advance a better understanding of inflammatory bowel disease.

A new firm threw its hat into the RNAi therapeutics ring this week, with San Diego startup Arcturus Therapeutics announcing that it has raised $1.3 million in seed financing to advance proprietary siRNA delivery and formulation technologies into in vivo proof-of-concept

NEW YORK (GenomeWeb News) – Microbiome company Second Genome today announced a deal with Johnson & Johnson's Janssen Biotech aimed at microbiome drug discovery.
Second Genome also announced it raised an additional $6.5 million in Series A financing.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.